DDInter1628 DDInter1492
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Ruxolitinib {u} (Compound) binds {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) PAFAH1B3
PAFAH1B3 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) binds {v} (Gene) RET
RET {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is regulated by {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) regulates {v} (Gene) PTPN6
PTPN6 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ruxolitinib (Compound) binds RET (Gene) and RET (Gene) is bound by Ponatinib (Compound)
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ponatinib (Compound)
Ruxolitinib (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) is upregulated by Ponatinib (Compound)
Ruxolitinib (Compound) downregulates PAFAH1B3 (Gene) and PAFAH1B3 (Gene) is downregulated by Ponatinib (Compound)
Ruxolitinib (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is downregulated by Ponatinib (Compound)
Ruxolitinib (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ponatinib (Compound)
Ruxolitinib (Compound) binds RET (Gene) and RET (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Ponatinib (Compound)
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is regulated by ABL1 (Gene) and ABL1 (Gene) is bound by Ponatinib (Compound)
Ruxolitinib (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) regulates PTPN6 (Gene) and PTPN6 (Gene) is upregulated by Ponatinib (Compound)